Home›Companies›Biotech & Pharma›Strand

Strand Therapeutics Inc.

Develops mRNA medicines for people with cancer and autoimmune diseases.

Updated Nov 10, 2026·Latest SEC filing Mar 17, 2026·Suggest an edit

About Strand

Strand is a private company based in Boston, Massachusetts. It has reported $166,130,518 raised in three offerings on Form D since June 2019. Its chief executive is Jacob Becraft.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
May 23, 2025Mar 17, 2026$108,099,927of $120.0M target10$10.8MEquityRule 506(b)Form D ↗
May 28, 2021Jul 27, 2021$52,143,967fully sold13$4.0MEquity, Series A and A-1 Preferred StockRule 506(b)Form D ↗
May 24, 2019Jun 7, 2019$5,886,624fully sold11$535KEquity, Series Seed Preferred StockRule 506(b)Form D ↗
Total, three offerings$166,130,518

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Strand's Form D filed Mar 17, 2026.

Jeb Keiper
Jeb Keiper
Independent Board Director
Also a director at Cardurion Pharmaceuticals.
Ala Alenazi
Ala Alenazi
Investment and director
Pegah Ebrahimi
Pegah Ebrahimi
Co-founder & Managing Partner, FPV Ventures, director
Also a director at Astra and Piston and an executive officer and director at FPV.
Tasuku Kitada
Tasuku Kitada
President, Head of R&D, Co-founder, director
Samta Kundu
Samta Kundu
Chief Operating Officer
Jory Bell
Jory Bell
Director
Also a director at Mangata Networks.
Jacob Becraft
Jacob Becraft
CEO, Co-Founder and director

Sources

  1. SECStrand Therapeutics Inc. filing history
  2. CompanyAbout Strand Therapeutics
  3. CompanyPrivacy policy